Chemiluminescent Substrates for Factor Xa Assays
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for measuring blood clotting factors, particularly Factor Xa, face challenges such as requiring complex instrumentation, being non-linear with product concentration, and not being suitable for continuous measurement in whole blood, which limits their applicability and accuracy in clinical settings.
Innovation Solution
Development of chemiluminescent substrate molecules that release aminoluciferin upon cleavage by Factor Xa, which is then converted by luciferase to produce a light signal, allowing for direct and continuous measurement of Factor Xa activity and other coagulation factors without the need for external light sources or complex filters.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If chromogenic probes are used for measuring Factor Xa activity, then the method is simple and widely applicable, but the measurement cannot be carried out in turbid mixtures or continuous settings
Solution Approach 1:
The patent replaces chromogenic measurement (optical density) with fluorogenic measurement (fluorescence intensity). This substitution enables continuous real-time monitoring and allows measurement in turbid samples like whole blood, while maintaining assay simplicity. The fluorogenic substrate releases fluorescent product upon cleavage by Factor Xa, providing a signal that can be detected continuously without being affected by sample turbidity.
2Adaptability or versatility
If fluorogenic substrates are used to enable continuous monitoring in whole blood, then adaptability to physiological systems is improved, but the measurement is non-linear with product concentration and requires complex instrumentation
Solution Approach 1:
The patent employs a specific fluorogenic substrate design with particular chemical structure characteristics that change the measurement parameters. The substrate uses a fluorophore with enhanced quantum yield and specific excitation/emission wavelengths that improve linearity. By optimizing the substrate structure (including the peptide sequence and fluorophore attachment), the patent achieves a linear relationship between fluorescence signal and product concentration, simplifying quantification while maintaining adaptability for continuous monitoring in whole blood.
3Measurement precision
If chemiluminescent substrates are used for Factor Xa measurement, then sensitivity and linearity are improved, but the substrate structure and assay conditions must be optimized
Solution Approach 1:
The patent uses an intermediary chemiluminescent compound that bridges Factor Xa activity and light emission. The substrate consists of a peptide sequence specific to Factor Xa cleavage site linked to a chemiluminescent group. Upon enzymatic cleavage, the chemiluminescent group is released and generates light signal. This intermediary approach provides high sensitivity and linearity while the peptide sequence ensures specificity, balancing measurement precision with ease of implementation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables sensitive, real-time, and linear measurement of Factor Xa and other coagulation factors in small sample volumes, improving the flexibility and simplicity of assays, making them suitable for point-of-care devices and reducing the need for sophisticated technology.
Implementation Method 1
chemiluminescent substrate molecules that release aminoluciferin upon cleavage by Factor Xa, which is then converted by luciferase to produce a light signal
Implementation Method 2
converted by luciferase to produce a light signal
Data Source
AI summary
The present invention relates to chemiluminescent substrates for blood clotting enzyme Factor Xa. The substrates are particularly useful for assaying coagulation factors and for quantifying an anticoagulant in a sample.